Aclaris Therapeutics (ACRS) logo

Aclaris Therapeutics (ACRS) stock

Inflammatory disease drugs , market cap $555M

$3.44
-1.71%

Why is ACRS down?

Down 8% on Nov 16, a down day for the market: the S&P 500 fell 2%, 76% of stocks fell, and biotech stocks a median 3%.

“Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD).”

Its release that day said

Sources: Price history, Nov 16, 2026; Company release (8-K), Nov 16, 2026

−2Growth sales down 59% on the year, gross margin down 6.5 points

Tell me next time ACRS moves

Free account, no card. An optional alert when ACRS moves or its score changes.Pro, $1 for a first month. An optional alert when ACRS moves or its score changes.Pro, 7 days free with a card. An optional alert when ACRS moves or its score changes.

Or see it live, free until Tuesday morning. No account.Or see one stock in full, free. No account.
1 more reason, free with an account →See every reason on ACRS →1 more reason why ACRS fell on Nov 16, from its filings, with how the business stands, the timeline, and its peers, for Pro members.

Why ACRS still beats the market over three years

Up 266% over the three years to Nov 20 while the S&P 500 rose 58%; down 8% on Nov 16.

1 reason, from its filings, with the timeline and its peers, for Pro members.

Quality Score
-7
Poor
In its industry
#211of 273
Checks firing
1of 14
Trending down
From 52-week high
-47.9%
under its best in a year

ACRS's Quality Score fell 2 points on Fri, Nov 20, to -7. Its quiet day ended (2 chart checks stopped).

Follow ACRS's trial news. Pro members can get an alert when Aclaris Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when ACRS files news on its trialsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2H 2026“Reaffirmed Expectation of Top Line Results in the Second Half of 2026…”Trial data · SEC filing · Aug 6
Cash$205M, about 10 quarters (2.5 years) at the last year's spendingOn Sep 30 · raised money since, not counted · the company says “Through the First Half of 2029”

Key facts on ACRS

Key facts on ACRS
Since its 2022 highDown 81% sales $29.8M → $6.4M a year
Latest filing8-K, Nov 16 Issued a release: "Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)"

ACRS in the news

Mon Nov 16Aclaris Therapeutics' mAb fails in Phase II eczema trial Yahoo Finance and 3 more ACRS closed −8.0% that day.

Big story

Mon Nov 16: Trial

Aclaris phase 2 atopic dermatitis trial fails primary endpoint

ACRS closed −8.0% that day on 3.1x normal volume.

Reported by Investing.com · covered by 4 outlets

What's next

Expected to report Thu Feb 25, before the open

After its last 4 reports it closed -2.5% on average, higher 1 of 4 times.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Cash$205M, about 10 quarters (2.5 years) at the last year's spendingOn Sep 30 · raised money since, not counted · the company says “Through the First Half of 2029”

ACRS catalysts

Coming up

4 more coming up and 4 past catalysts since 2026, with sizes and sources, for Pro members.

What's next for ACRS, and how long its cash lasts

Next step the company has named

2H 2026“Reaffirmed Expectation of Top Line Results in the Second Half of 2026 from Two Ongoing Phase 1b POC Trials of ATI- 052: ATI-052 is being assessed in POC trials in both atopic dermatitis…”Trial data · SEC filing · Aug 6

What it means: the first look at a trial’s main results, as the company reports them.

Lead program
ATI-052
Another trial
ALPHAPhase 2 · Recruiting · 102 people · main data estimated Mar 2029 · NCT07935590

1 more trial, 5 more milestones and 35 filings, for Pro members.

Cash runway Sep 30 balance sheet

About 10 quarters

$205M in cash and investments (as the company counts them), at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's estimate is “Through the First Half of 2029” (8-K, Nov 5). It has raised money since that balance sheet, which is not counted here.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3ASR, filed Aug 6, 2026)
  • At-the-market share sales program (S-3ASR, filed Aug 6, 2026)

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

No open-market buys or sales by its officers or directors in their filings of the last year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Neal Walker’s 21 filings and quotes.

Get an alert when ACRS files news on its trialsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

How ACRS ranks in Biotech

ACRS is #211 of 273 by Quality Score.

How ACRS ranks in Biotech
RankStockQuality Score
211Aclaris Therapeutics (ACRS) logoACRSAclaris Therapeutics-7

More in Biotech

When does ACRS report earnings, and what happens after?

Expected to report Thu Feb 25, before the open (in 96 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What ACRS reported on Nov 5, 2026

The quarter

Sales of $1.5M, 55% less than a year ago; a loss of $0.12 a share, from $0.12.

“The decreases were primarily driven by a sales milestone achieved under the Sun Pharma license agreement during the quarter and nine months ended September 30, 2025.”

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

Where the quarter's sales came from
LineQ3
2026
Q2
2026
Q3
2025
By product
License and Servicedown 58%$1.2M80%$1.3M78%$2.8M85%

Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 5)

1 more line, for Pro members.

The outlook

No outlook figures read from this release.

In the company's words

  • “The increases were primarily driven by expenses related to ATI-052, including product candidate manufacturing costs and clinical development expenses associated with Phase 1b programs in AD and asthma, as well as product candidate manufacturing costs and preclinical development expenses for ATI-9494.”

From its results filing (SEC filing · Nov 5)

1 more sentence, for Pro members.

The numbers

Market value
$555M
today
Sales
$6.4M
down 59.3% on the year
Free cash flow
-$75.3M
last 12 months

2 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on ACRS: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+1.7%-4.3%-1.9%
May 7Aug 6Nov 5
ReportedGapReaction5
days
Nov 5, 2026Before open+0.8%-1.9%+17.9%
Aug 6, 2026Before open-0.3%-4.3%-8.2%
May 7, 2026Before open-2.4%+1.7%+6.5%

ACRS closed higher after 1 of its last 4 reports.

All 4 reports, and ACRS's Quality Score going into each

ACRS sales and profit by year

Sales and profit by year

Sales grew in four of the last seven years, to $7.8M in 2025. It lost money in each of the eight years.

ACRS has 1 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on ACRS, and all 14 on every stock.Get in free →See the top 3 →Start Pro

ACRS RSI on Nov 20: 39.0, below its 50-day and 200-day averages

Not scored

RSI 39.0, MACD below signal, below both averages. Not scored.

The deep dive on ACRS

  • What it does and how it makes money5 findingsLicenses and services made up 76% of its revenue in fiscal 2025 ($5.95M of $7.83M), against 86% in fiscal 2024; contract research 24%.SEC filing · Feb 26, 2026"Our issued U.S. patents directed to ATI-2138 and methods of use expire in 2039." (10-K for fiscal 2025)SEC filing · Feb 26, 2026
  • What changed in its filings1 findingA new heading in its "Risk Factors" this year: "The rapid advancement of artificial intelligence and computational drug discovery technologies could make our KINect platform and discovery approaches less competitive or obsolete …" (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Feb 26, 2026, against the one of Feb 27, 2025
  • Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades ACRS, for Pro members

5 more findings on ACRS, each with its source, for Pro members.

ACRS share count over time

22% more shares than a year earlier.

Weighted shares, quarter to Sep 30, 2026, both from one filing

Shares of ACRS outstanding, as filed
Shares
outstanding
As
of
158.6MOct 30, 2026
147.2MJul 31, 2026
139.7MApr 30, 2026
120.6MJan 30, 2026
Offerings, shelves, and splits of ACRS, from its filings
From its
filings
Filed
Priced a sale of sharesOct 27, 2026
Registered shares for a later sale (S-3ASR)Aug 6, 2026
Registered shares for a later sale (S-3)Feb 27, 2025
Registered shares for a later sale (S-3)Dec 19, 2024

ACRS's officers and directors

Officers and directors with a Form 4 in the last 12 months.

4 more officers and directors file at ACRS.

See insider trades by person

Which ETFs hold ACRS?

In ETFs: ACRS is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Aclaris Therapeutics

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

73 employeesWayne, PAaclaristx.com

What Aclaris Therapeutics says it competes with

“The pharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary drugs.”

From its annual report, SEC filing · Feb 26, 2026

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on ACRS and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn ACRS's score around: 9 things
  • 9 more filings explained, a plain line each
  • 5 more things pulling ACRS's score down

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: ACRS's Quality Score is -7 (Poor), #211 of 273 in Biotech.

What does ACRS's Quality Score say?

ACRS scores -7 today, which Breakaway calls Poor. It is #211 of 273 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 8% on Nov 16, a down day for the market: the S&P 500 fell 2%, 76% of stocks fell, and biotech stocks a median 3%. Cash lasts about 10 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is ACRS's Quality Score?

ACRS scores -7 today, which Breakaway calls Poor (below zero). That is #211 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ACRS's -7.

When does ACRS report earnings?

Expected to report Thu Feb 25, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. ACRS closed higher after 1 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Aclaris Therapeutics: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.